# Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life

> **NCT01735084** · PHASE4 · COMPLETED · sponsor: **Menzies School of Health Research** · enrollment: 261 (actual)

## Conditions studied

- Otitis Media
- Febrile Illness
- Cough
- Lower Respiratory Tract Infection
- Upper Respiratory Tract Infection

## Interventions

- **BIOLOGICAL:** Prevenar13
- **BIOLOGICAL:** Synflorix

## Key facts

- **NCT ID:** NCT01735084
- **Lead sponsor:** Menzies School of Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-12
- **Primary completion:** 2019-02-14
- **Final completion:** 2019-10-03
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2020-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01735084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01735084, "Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01735084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*